(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 May 2024 (16.05.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/099992 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 25/28* (2006.01)
A61P 11/06 (2006.01) *A61K 31/53* (2006.01)
A61P 25/16 (2006.01)

(21) International Application Number:
PCT/EP2023/080895

(22) International Filing Date:
07 November 2023 (07.11.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
22206271.3 09 November 2022 (09.11.2022) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BOUCHE, Lea Aurelie**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **GUBA, Wolfgang**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **JAESCHKE, Georg**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **MESCH, Stefanie Katharina**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **SHANNON, Jonathan Martin**; c/o Sygnature Discovery Limited, The Discovery Building, BioCity, Pennyfoot Street, Nottingham NG1 1GR (GB). **STEINER, Sandra**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **TOSSTORFF, Andreas Michael**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH).

(74) Agent: **JOCHNOWITZ, Evan**; c/o F. Hoffmann-La Roche AG, Patent Department, Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title:** TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS



(I)

(57) **Abstract:** The invention relates to novel compounds having the general formula (I) wherein R^1, R^2, R^3, R^4 and R^5 are as described herein, composition including the compounds and methods of using the compounds.

WO 2024/099992 A1